Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975893 · ClinicalTrials.gov registry record · Phase 2
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT04975893 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 135 participants.
The verdict
NCT04975893, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202 (NCT04232280). For participants in the optional booster phase (BP), the main purpose is to evaluate the long-term immunogenicity and safety of the mRNA-1647 vaccine in both participants receiving a booster dose (BD) and those not receiving a BD, and to additionally evaluate the reactogenicity in participants receiving a BD.
Interventions
- BIOLOGICAL mRNA-1647
- OTHER mRNA-1647
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2026-01-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975893
The ClinicalTrials.gov registry entry for NCT04975893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mRNA-1647 is the first listed.
NCT04975893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04975893 about?
NCT04975893 is a clinical study titled "A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine". The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202 (NCT04232280). For participants in the optional booster phase (BP), the main pu...
What is the current status of trial NCT04975893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2021-06-18. Estimated completion is 2026-01-19.
What interventions are being tested in trial NCT04975893?
The interventions under investigation include: mRNA-1647 (BIOLOGICAL), mRNA-1647 (OTHER).
Who is sponsoring clinical trial NCT04975893?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.